| Assessment Status | Rapid Review Complete |
| HTA ID | 26021 |
| Drug | Tislelizumab |
| Brand | Tevimbra® |
| Indication | Tislelizumab (Tevimbra®) in combination with platinum containing chemotherapy (ChT) is indicated as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment, for the treatment of adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence. |
| Assessment Process | |
| Rapid review commissioned | 12/05/2026 |
| Rapid review completed | 17/06/2026 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that tislelizumab in combination with platinum-containing ChT for this indication not be considered for reimbursement at the proposed price. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here
Further information on the status of this decision may be found here